BCRX vs ECL · $1.83B cap vs P/E 35, rev $4.01B
BioCryst Pharmaceuticals Inc (BCRX) versus Ecolab Inc (ECL) — a side-by-side from cached financials, not a winner call.
BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on US.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
BCRX does not have a complete income-statement cache yet.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
BCRX currently screens at market cap $1.83B. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Not investment advice. Open the BCRX and ECL stock pages for the full models.
Not investment advice.